Lilly’s Olomorasib Gets FDA Breakthrough Therapy Nod for New Metastatic KRAS G12C Lung Cancer…
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib, in combination with KEYTRUDA…
Read More...
Read More...
